​(GA-1) Glutaric Acidemia Type 1 aka ​Glutaryl CoA Dehydrogenase Deficiency Type 1

Glutaric acidemia type 1 is an inherited disorder in which the body is unable to process certain proteins properly. People with this disorder have inadequate levels of an enzyme that helps break down the amino acids lysine, hydroxylysine and tryptophan, which are building blocks of protein. Excessive levels of these amino acids and their intermediate breakdown products can accumulate and cause damage to the brain, particularly the basal ganglia, which are regions that help control movement. Mental retardation may also occur. The severity of glutaric acidemia type 1 varies widely; some individuals are only mildly affected, while others have severe problems. Some babies with glutaric acidemia type 1 are born with unusually large heads (macrocephaly). Affected individuals may have difficulty moving and may experience spasms, jerking, rigidity or decreased muscle tone. Some individuals with glutaric acidemia have developed bleeding in the brain or eyes that could be mistaken for the effects of child abuse. Strict dietary control may help limit progression of the neurological damage. Stress caused by infection, fever or other demands on the body may lead to worsening of the signs and symptoms, with only partial recovery.
Research & Studies

Research study for patients with PDE or GA 

We are recruiting patients and families for the CHARLIE metabolism Project (CHAnging Rare disorder of LysINe metabolism). This is an international collaboration focused on developing novel therapies for patients with pyridoxine-dependent epilepsy (PDE) and glutaric aciduria type I (GA I).  Both substrate reduction therapy (an upstream block of lysine metabolism) and gene replacement therapy will be trialed in model systems such as neuronal stem cells, mouse, and zebrafish models.  The CHARLIE project is led by Professor Clara van Karnebeek at the University of Amsterdam UMC in the Netherlands.

Although this is a basic-research focused project, we also want to work closely with patients and families in order to describe the needs and wishes of families and to define goals of care that are essential to improve quality of life. This project (referred to as “patients in the lead”) is led by Hanna Dekker who is the director of the VKS (a Dutch patient support organization).  https://www.stofwisselingsziekten.nl/

If you are interested in more information or in participating, please contact Dr. Curtis Coughlin II at the University of Colorado (Curtis.Coughlin@cuanschutz.edu, 303.724.3839)

Meet Our Children With GA-1

Meet Our Kids

Recent Articles

Demo Derby Sibling Honors Brother and others with Organic Acidemias!
Meadow, 3-MCC
Leo – Isovaleric Acidemia, Age 20 months
Summer 2023 OAA Newsletter (Digital Version Available Now!)
Webinar Discussion on Liver/Kidney Transplant with other OAA Families
Join Us for a Dietician Talk-Exclusively for OAA Families
Update on the Rapid Blood Ammonia Testing Instrument
Katie – Glutaric Acidemia, Type 1
Cameron, Methylmalonic Acidemia, Cbl C, Age 6 years
Nolan, Propionic Acidemia, Age 18 months
Winter 2023 OAA Newsletter (Digital Version Available Now!)
Select Language